Idiopathic Pulmonary Fibrosis (IPF) Pipeline, A Novel Advancement for the Treatment of Cancer

The study analyzed that the IPF pipeline comprised of 97 therapeutic candidates, of which 15 are in Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. Various drugs are being developed as novel and promising therapeutics for the treatment of IPF.

Browse the Report Summary at: www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market
Insights on pipeline segments

As per the findings of research, it was found that around 9% IPF candidate target chemokine, 7% target integrin and 6% of the product candidates target G-protein couple receptor. Other targets comprising 78% of candidates of IPF pipeline include, but not limited to, autotaxin, connective tissue growth factor-associated, fibroblast growth factor, lysyl-oxidase like protein 2 and tissue growth factor beta. Around 55% pipeline therapeutic candidates of IPF are being developed to be administered by oral route, 20% by inhalation route, 12% by intravenous route and 8% by subcutaneous route.

Phase III stage of development consist of only one IPF drug

Thrombomodulin Alfa (ART-123) is under Phase III stage of development by Asahi Kasei Pharma Corporation for the treatment of IPF. It is already marketed in Japan under the name of Recomodulin for the treatment of disseminated intravascular coagulation. Thrombomodulin Alfa is a soluble recombinant human thrombomodulin and inhibits the coagulation process by accelerating the activation of protein C by thrombin. The drug candidate is administered by intravenous route.

Browse Report Sample at: www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market/report-sample

Phase II stage of development is crowded with number of promising drugs

There are total 15 drug candidates in Phase II stage of development for the treatment of IPF. GLPG1690 is under Phase II stage of development by Galapagos NV for the treatment of IPF. The drug candidate targets lysophosphatidic acid 1 (LPA1) receptor also known as autotaxin and inhibits its action. The company plans to disclose the Phase II topline results for IPF in the first half of 2017. In February 2015, Galapagos NV released the Phase I study results for GLPG1690 (NCT02179502). GLPG1690 proved to be safe and well-tolerated over a wide dose range in healthy volunteers. The drug candidate showed favorable pharmacokinetic and pharmacodynamic profile. In this trial, GLPG1690 demonstrated the ability to reduce plasma lipid lysophosphatidic acid (LPA) levels on a sustained basis, implying ATX engagement.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com

347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)

This release was published on openPR.